Drug maker Granules India today said US health regulator FDA has inspected its Gagillapur manufacturing facility near Hyderabad and did not find any deviation from good manufacturing norms.
"The United States Food and Drug Administration (USFDA) had inspected Gagillapur facility last week and the inspection concluded with no observations," Granules India said in a filing to BSE.
The inspection was triggered by one of the applicant's Abbreviated New Drug Application (ANDA) filing, it added.
The company manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages at its Gagillapur facility.
Shares of Granules India today closed at Rs 908.70 per scrip on BSE, up 3.43 per cent from its previous close.
